Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma

Alexander MM Eggermont, Andrey Meshcheryakov, Victoria Atkinson, Christian U. Blank, Mario Mandala, Georgina V. Long, Catherine Barrow, Anna Maria Di Giacomo, Rosalie Fisher, Shahneen Sandhu, Ragini Kudchadkar, Pablo Luis Ortiz Romero, Inge Marie Svane, James Larkin, Susana Puig, Peter Hersey, Pietro Quaglino, Paola Queirolo, Daniil Stroyakovskiy, Lars BastholtPeter Mohr, Micaela Hernberg, Vanna Chiarion-Sileni, Matthew Strother, Axel Hauschild, Naoya Yamazaki, Alexander CJ van Akkooi, Paul Lorigan, Clemens Krepler, Nageatte Ibrahim, Sandrine Marreaud, Michal Kicinski, Stefan Suciu, Caroline Robert

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

15 Citaten (Scopus)

Vingerafdruk

Duik in de onderzoeksthema's van 'Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma'. Samen vormen ze een unieke vingerafdruk.

Medicijnen en Levenswetenschappen